Home > Insider Trading > Filing (0001209191-12-057176)

Filing Details

Accession Number:: 0001209191-12-057176
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2012-12-12 17:13:41
Reporting Period:: 2011-12-20

Filing Date:: 2012-12-12
Accepted Time:: 2012-12-12 17:13:41
Original Submission Date:: 2011-12-22
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1235007	Endocyte Inc	ECYT	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1267980	V Management Ventures Sanderling	400 S. El Camino Real, Suite 1200 San Mateo CA 94402		No	No	Yes	No
1429588	Vi Management Ventures Sanderling	400 S. El Camino Real, Suite 1200 San Mateo CA 94402		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2011-12-20	1,589	$3.20	32,355	No	4	P	Indirect	By Sanderling Ventures Management VI
Common Stock	Acquisiton	2011-12-21	1,589	$3.16	33,944	No	4	P	Indirect	By Sanderling Ventures Management VI

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Sanderling Ventures Management VI
No	4	P	Indirect	By Sanderling Ventures Management VI

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	149,003	Indirect	By Sanderling Ventures Management V

Footnotes

The form 4 is being amended to correct the number of shares acquired and the number of shares beneficially owned by the reporting persons following the acquisitions which was incorrectly reported in original filing.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.14 to $3.27, inclusive. The reporting person undertakes to provide Endocyte, Inc., any security holders of Endocyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Fred Middleton is the owner of Sanderling Ventures Management V and Sanderling Ventures Management VI Partnership and he may be deemed to have voting and investment power over shares held of record by Sanderling Ventures Management V and Sanderling Ventures Management VI Partnership. Mr. Middleton disclaims beneficial ownership of the shares directly held by the entities affiliated with Sanderling except to the extent of his individual pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.10 to $3.21, inclusive. The reporting person undertakes to provide Endocyte, Inc., any security holders of Endocyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.